Comparing two drug-releasing heart stents in people with acute coronary syndrome
Compares two drug-releasing stents in people with sudden heart artery blockage.
Plain-language title generated from the registry record
Registry title: Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions
Key facts
- Where
- Alicante, Badalona, Barakaldo, Barcelona, Castelló, Donostia / San Sebastian, El Palmar, Fuencarral-El Pardo, Huelva, L'Hospitalet de Llobregat, León, Lleida, Lugo, Málaga, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Tarragona, and Zaragoza, SpainSee the 20 sites
Where in Spain
- Hospital Universitario San Juan AlicanteAlicante, SpainTaking people
- Hospital Universitari Germans Trias i PujolBadalona, SpainTaking people
- Hospital Universitario de CrucesBarakaldo, SpainTaking people
- Hospital Clinic de BarcelonaBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital General Universitario de CastellónCastelló, SpainTaking people
- Hospital Universitario de DonostiaDonostia / San Sebastian, SpainTaking people
- Hospital Universitario Virgen de la ArrixacaEl Palmar, SpainTaking people
- Hospital Universitario La PazFuencarral-El Pardo, SpainTaking people
- Hospital Universitario Juan Ramon JimenezHuelva, SpainTaking people
- Hospital Universitari de BellvitgeL'Hospitalet de Llobregat, SpainTaking people
- Hospital Universitario De LeonLeón, SpainTaking people
- Hospital Universitari Arnau de VilanovaLleida, SpainTaking people
- Hospital Universitario Lucus AgustiLugo, SpainTaking people
- Hospital Regional Universitario de MalagaMálaga, SpainTaking people
- Hospital Universitario de CanariasSan Cristóbal de La Laguna, SpainTaking people
- Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
- Hospital Clínico Universitario de SantiagoSantiago de Compostela, SpainTaking people
- Hospital Universitari de Tarragona Joan XXIIITarragona, SpainTaking people
- Hospital Clinico Universitario Lozano BlesaZaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación EPIC
- Trial code
- NCT07190690
- Record updated
- 10 August 2026
- Original description
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).Read full original descriptionShow less
Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions (DestinACSion Study)
To evaluate the efficacy of the two DES (Drug Eluting Stent) used in terms of device-related adverse events at 12 months after PCI (Percutaneous Coronary Intervention).
To compare the clinical safety and efficacy by comparing net clinical events (defined as the combination of ischemic and hemorrhagic events) of the two DES used at 12 months after PCI.
Inclusion: Patients who meet ALL inclusion criteria will be included:; Patients aged ≥18 years, and; Patients diagnosed with an acute coronary syndrome (ACS), either SCASEST (Acute Coronary Syndrome without Persistent ST-Segment Elevation) or IAMCEST (Acute Myocardial Infarction with Persistent ST-Segment Elevation), for which they will undergo PCI, and; Patients with de novo lesions in vessels with a reference diameter of ≥2.25 mm and ≤4.5 mm in whom implantation of one or more DES is clinically indicated, and; Patients who have been informed of the characteristics of the study and have provided written informed consent.
Exclusion: Patients with planned surgery within the next 3 months; Patients with a known hypersensitivity or allergy to aspirin or any P2Y12 receptor inhibitor (clopidogrel, prasugrel, ticagrelor), heparin, contrast agents, or any of the components of DES; Patients with active bleeding at the time of PCI requiring medical attention; Patients with any medical condition that limits a life expectancy of less than 12 months; Patients must not meet any of the following exclusion criteria:; Patients in cardiogenic shock according to the severity criteria defined by the Society of Cardiovascular Angiography and Interventions (SCAI): "C" (Classic Shock), "D" (Deteriorating) and "E" (Extremis); Patients unable to provide informed consent; Patients participating in another clinical trial in which the primary endpoint was not met; Pregnant or breastfeeding women of childbearing potential with a positive pregnancy test.